Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
94 hedge funds and large institutions have $589M invested in Epizyme, Inc in 2016 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 11 closing their positions.
31% more capital invested
Capital invested by funds: $450M → $589M (+$139M)
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $1.09M
3% less funds holding
Funds holding: 97 → 94 (-3)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$13.7M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$4.96M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.76M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$2.31M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$3.34M |
| 2 |
Renaissance Technologies
New York
|
-$1.77M |
| 3 |
SCA
Secor Capital Advisors
New York
|
-$1.67M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$1.48M |
| 5 |
Millennium Management
New York
|
-$1.35M |
EPZM Hedge Fund Activity: Q4 2016 in Review
94 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2016, worth a combined $589M — up 31% from $450M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of EPZM and 9 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 32 added.
The largest buyer was Deerfield Management, adding an estimated $13.7M. The largest seller was QVT Financial, cutting an estimated $3.34M.
- 94 institutional investors held Epizyme, Inc (EPZM) as of Q4 2016, down from 97 in Q3 2016.
- Funds reported $589M of Epizyme, Inc stock for Q4 2016, up 31% quarter-over-quarter.
- 9 funds opened new Epizyme, Inc positions in Q4 2016 and 11 closed out, a net change of -2 holders.
- The largest Epizyme, Inc buyer in Q4 2016 was Deerfield Management, an estimated $13.7M added.
- The largest Epizyme, Inc seller in Q4 2016 was QVT Financial, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2016.